Loading...
XNASICUI
Market cap3.84bUSD
Dec 24, Last price  
156.89USD
1D
1.42%
1Q
-10.21%
Jan 2017
6.47%
Name

ICU Medical Inc

Chart & Performance

D1W1MN
XNAS:ICUI chart
P/E
P/S
1.70
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
2.21%
Rev. gr., 5y
10.04%
Revenues
2.26b
-0.92%
75,550,000157,532,000201,613,000188,138,000204,726,000231,513,000284,582,000302,195,000316,869,000313,716,000309,260,000341,668,000379,372,0001,292,613,0001,400,040,0001,266,208,0001,271,004,0001,316,308,0002,279,997,0002,259,126,000
Net income
-30m
L-60.08%
5,000,00020,274,00025,660,00023,079,00024,300,00026,557,00030,929,00044,669,00041,281,00040,418,00026,335,00044,985,00063,084,00068,644,00028,793,000101,035,00086,870,000103,135,000-74,286,000-29,655,000
CFO
166m
P
25,283,00027,372,00031,608,00041,512,00030,227,00048,609,00033,095,00064,487,00066,271,00064,020,00060,640,00054,865,00089,941,000154,423,000160,215,000101,918,000222,752,000267,538,000-62,129,000166,201,000
Earnings
Feb 25, 2025

Profile

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
IPO date
Mar 31, 1992
Employees
14,500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,259,126
-0.92%
2,279,997
73.21%
1,316,308
3.56%
Cost of revenue
1,604,597
1,675,220
872,316
Unusual Expense (Income)
NOPBT
654,529
604,777
443,992
NOPBT Margin
28.97%
26.53%
33.73%
Operating Taxes
(48,644)
(40,123)
20,051
Tax Rate
4.52%
NOPAT
703,173
644,900
423,941
Net income
(29,655)
-60.08%
(74,286)
-172.03%
103,135
18.72%
Dividends
Dividend yield
Proceeds from repurchase of equity
(9,350)
(2,098)
1,037
BB yield
0.39%
0.06%
-0.02%
Debt
Debt current
71,161
29,688
9,009
Long-term debt
1,707,783
1,704,615
81,085
Deferred revenue
10,585
16,239
202
Other long-term liabilities
74,037
165,233
26,200
Net debt
1,521,101
1,520,779
(481,773)
Cash flow
Cash from operating activities
166,201
(62,129)
267,538
CAPEX
(83,893)
(99,329)
(81,169)
Cash from investing activities
(87,947)
(1,909,468)
(90,687)
Cash from financing activities
(35,979)
1,637,032
(16,870)
FCF
700,080
106,934
476,435
Balance
Cash
254,723
213,008
567,247
Long term investments
3,120
516
4,620
Excess cash
144,887
99,524
506,052
Stockholders' equity
757,179
758,922
894,646
Invested Capital
3,767,002
3,819,039
1,179,974
ROIC
18.54%
25.80%
35.41%
ROCE
16.50%
14.95%
26.31%
EV
Common stock shares outstanding
24,091
23,868
21,781
Price
99.74
-36.66%
157.48
-33.65%
237.34
10.65%
Market cap
2,402,836
-36.07%
3,758,733
-27.29%
5,169,503
11.63%
EV
3,923,937
5,279,512
4,687,730
EBITDA
883,320
839,928
533,690
EV/EBITDA
4.44
6.29
8.78
Interest
102,727
66,375
858
Interest/NOPBT
15.69%
10.98%
0.19%